• Delcath Systems: Filtering Through Its Past & Future

  • Oct 24 2021
  • Length: 48 mins
  • Podcast

Delcath Systems: Filtering Through Its Past & Future

Listen for free

View show details

  • Summary

  • An interview with Gerard Michel, CEO of Delcath Systems, where Gerard reflects back on his time with Vericel, the decision to become CEO of Delcath, the initial NDA submission for the HEPZATO™ KIT, and the preliminary data release from the Phase 3 FOCUS study. Gerard also addresses the future for Delcath, including the impending full Phase 3 FOCUS results, future clinical indications to be pursued with the HEPZATO™ KIT, and commercial dynamics in the interventional oncology space.

    Companies discussed during the podcast:

    Delcath Systems, Inc (Nasdaq: DCTH)

    Vericel Corporation (Nasdaq: VCEL)

    Immunocore Ltd (Nasdaq: IMCR)

    Bright Minds Biosciences (OTCQB: BMBIF, CSE: DRUG)

    Gerard Michel, CEO of Delcath Systems, Inc. (“Delcath”) appeared on this episode of the podcast. Listeners are urged to review Delcath’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Delcath undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Delcath Systems: Filtering Through Its Past & Future

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available